neuro Optical Coherence Tomography
Spryte Medical Receives Breakthrough Device Designation from FDA for Revolutionary neuro Optical Coherence Tomography (nOCT) Technology
“Our engagement with the FDA through the Breakthrough Device and Total Product Life Cycle Advisory Program (TAP), highlights the potential of Spryte Medical’s neuro OCT imaging platform for patients with cerebrovascular disease” said David Kolstad, Chief Executive Officer of Spryte Medical. “We look forward to working collaboratively with the FDA for the benefit of these patients.”
